Marbofloxacin is a synthetic, bactericidal antimicrobial, belonging to the fluoroquinolonegroup. It acts by inhibition of DNA gyrase enzyme of microbial cell. The in vitro activity of marbofloxacin has been demonstrated towards Pasteurellamultocida, Mannheimia haemolytica and Escherichia coli.
– Therapeutic treatment of respiratory infections caused by sensitive strains of Pasteurellamultocida and Mannheimia haemolytica.
– Acute mastitis in lactating cows caused by E.coli.
Use of the product should only be based on susceptibility testing.
– If the volume to be injected intramuscularly is more than 20 ml, it should be divided between two or more injection sites.
– To ensure a correct dosage,bodyweight should be determined as accurately as possible to avoid underdosing.
– Do not use in animals with known hypersensitivity to fluoroquinolones or to any of the excipients.
– Do not use in cases where the pathogen involved is resistant to other fluoroquinolones (cross resistance).
– Administration by the intramuscular route may cause rare transient local reactions such as pain and swelling at the injection site which may persist up to 7 days after injection.
– Fluoroquinolones are known to induce arthropathies.
– Lesions of the joint cartilage were observed in some animals treated at 10 mg/kg or 30 mg/kg for three times the recommended treatment duration, but did not induce clinical signs. Moreover, no sign of overdosage was observed throughout this study.